Author: LEVIN JEREMY DU MILA
Publisher: Taylor & Francis Ltd
ISSN: 1055-9612
Source: Drug Design and Discovery, Vol.18, Iss.4, 2003-01, pp. : 123-126
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Sulfonamide hydroxamate derivatives of anthranilic acids are known to be potent inhibitors of cell-free TACE enzyme. However, compounds of this structural class with both high potency and high selectivity for TACE over matrix metalloproteinases (MMPs) are uncommon. Replacement of the sulfonamide functionality with an isosteric sulfonate ester has resulted in a series of sulfonate ester hydroxamates, 2a–e, with excellent activity against TACE and excellent selectivity over MMP-1 and MMP-13. Although compounds 2a–e possess good permeability in a PAMPA assay, they are only weakly active as inhibitors of lipopolysaccharide (LPS)-stimulated tumor necrosis factor (TNF) production in human monocytic THP-1 cells. Protein binding affinity also does not predict the lack of cellular activity for these analogs.
Related content
Arylsulphonamide hydroxamic acids as potent inhibitors of MMP-13
Expert Opinion on Therapeutic Patents, Vol. 9, Iss. 9, 1999-09 ,pp. :
Hydroxamic Acids Designed as Inhibitors of Urease
Letters in Drug Design & Discovery, Vol. 6, Iss. 3, 2009-04 ,pp. :
By Deng Xinxian Liu Jingbao Jin Yan Zhang Yong He Wan Bao Jian Liu Wenlu Jiang Faqin Fu Lei
Die Pharmazie - An International Journal of Pharmaceutical Sciences, Vol. 70, Iss. 12, 2015-12 ,pp. :